MSD in the news

MSD's drug tulisokibart met its primary endpoint in a Phase IIb study for hidradenitis suppurativa, with high and medium doses outperforming placebo.

MSD's tulisokibart met its primary endpoint in a Phase IIb study for hidradenitis suppurativa, showing efficacy in high and medium doses.

MSD announced positive Phase 2b trial results for tulisokibart in moderate to severe hidradenitis suppurativa, showing superior efficacy over placebo.

MSD Korea launched Keytruda SC, a subcutaneous cancer drug, drastically cutting administration time to 1-2 minutes for 35 indications, with unresolved pricing and reimbursement.

PAHO and MSD for Mothers partnered on a two-year initiative to reduce preventable maternal deaths and adolescent pregnancies in Guatemala and the Dominican Republic.

MSD licensed a preclinical KRAS inhibitor, SPR2015, from SciBrunch Therapeutics for up to $2.13 billion, aiming to diversify its pipeline ahead of Keytruda's patent expiry.

MSD initiated a Phase I clinical trial for a drug candidate using Cyprumed's oral tablet technology, marking Cyprumed's first technology program to enter human clinical development and triggering a milestone payment.

MSD is accelerating phase 3 trials for MK-8748, an ophthalmic drug candidate licensed from Ingenia, for diabetic macular edema and neovascular age-related macular degeneration.

MSD acquired a global license for SciBrunch Therapeutics' KRAS G12D inhibitor, SPR2015, for $400 million upfront, targeting a common cancer mutation with no approved therapies.

MSD appointed Vidhya Sundaram as AVP, Global Technology Centers to lead its Hyderabad Tech Center and global technology strategy.

MSD and Daiichi Sankyo withdrew their US regulatory filing for the lung cancer candidate ifinatamab deruxtecan (I-DXd) after the FDA deemed its phase 2 trial data insufficient for accelerated approval.

MSD appointed Vidhya Sundaram as Associate Vice President, Global Technology Centers and Hyderabad Tech Center Lead, leveraging her two decades of experience to enhance technology strategy and digital capabilities.

Daiichi Sankyo and MSD withdrew their cancer drug application for ifinatamab deruxtecan due to insufficient data for FDA accelerated approval.

MSD's experimental eye drug, remigromig, achieved the primary endpoint in a trial for diabetic macular edema, showing similar efficacy to an existing treatment.

Bio Farma and MSD expanded their partnership to boost Indonesia's local vaccine manufacturing and technology transfer for PCV15 and HPV vaccines.

MSD's acquisition of EyeBio has yielded a positive Phase 3 trial for remigromig, a novel Wnt drug for diabetic macular oedema, marking a significant return to ophthalmology.

MSD's remigromig, a new diabetic macular oedema drug, demonstrated non-inferiority to Lucentis in late-stage trials despite some tolerability concerns.

MSD's new diabetic macular oedema drug, remigromig, demonstrated non-inferiority to Lucentis in late-stage trials but showed higher rates of adverse events.

MSD successfully imported Naltrexone to treat alcohol addiction in Tanzania through a partnership with Mirembe National Mental Health Institute, following a government directive.

MSD is working with Ghana to strengthen women's cancer care and healthcare systems through policy discussions and partnerships.